Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals

Drug Profile

Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals

Alternative Names: 60P 003; Arakoda; Etaquine; KODATEF; Kozenis; Krintafel; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine maleate; Tafenoquine succinate; WR 238605; WR 238605 succinate

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer 60 Degrees Pharmaceuticals; Biocelect; GlaxoSmithKline; GSK; Medicines for Malaria Venture
  • Class Aminoquinolines; Antifungals; Antimalarials; Antiprotozoals; Antivirals; Ethers; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action Electron transport complex III inhibitors; Reactive oxygen species stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Marketed Malaria
  • Phase II COVID 2019 infections
  • Preclinical Babesiosis; Mycoses
  • Discontinued Pneumocystis pneumonia

Most Recent Events

  • 20 Feb 2024 60 Degrees Pharmaceuticals plans a Preclinical trial for Mycoses in Australia in the second quarter of 2024 (Parenteral)
  • 26 Dec 2023 60 Degrees Pharmaceuticals plans a phase IIa trial in Babesiosis in USA (PO) in Q2 2024
  • 26 Dec 2023 60 Degrees Pharmaceuticals plans a pre-IND meeting with the US FDA for Babesiosis before the end of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top